Lundbeck is entering into a psychiatric disorders with the Lieber Institute, which has the world’s largest collection of human brains from patients with psychiatric disorders.
This collaboration will enable Lundbeck’s researchers to take decisive steps towards new and better treatment of the debilitating and life-long brain disease that is schizophrenia.
This joint project provides a unique opportunity to investigate how genes affect brain development and disorders of the brain.
Based on knowledge of the biology of brain disease, researchers will simply be able to look at the brains of both sick and healthy individuals and establish a nuanced picture of how the biology of the disease can be expressed.
For further deal information visit Current Agreements (subscription required)
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Big Pharma
Report: Partnering Deals and Alliances with Lundbeck
Related reports: Alzheimer’s Disease Partnering
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity